CALITHERA BIOSCIENCES INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. The funds will be used to expand the firmâ s range of marketing and advertising services. Industry Pharmaceuticals. Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. When the results of an employee survey came through in May 2020, Nucleus Global CEO Dan Bridges, who is based in London, clicked open the file … and breathed a huge sigh of relief: 98% of employees gave the leadership team high marks for its handling … Click here for webcast. Apr 2013 – Present6 years 8 months. Well, this is Susan. Thanks all for joining today and have a good evening. Insider Ownership Of Calithera Biosciences. Who Participates Biotech… Read More About Published: April 29, 2016. SOUTH SAN FRANCISCO, Calif., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that preliminary safety and efficacy data from an investigator-sponsored trial … SOUTH SAN FRANCISCO, Calif., Feb. 3, 2015 -- Calithera Biosciences, Inc. , a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against... | May 23, 2021 The Company is focused on discovering and developing novel … Corporate Profile. Phone 1 650 870-1000. All content is posted anonymously by employees working at Calithera Biosciences. CALA stock has a five-year performance of -52.5 %. On Tuesday, February 14, 2017, Susan Molineaux, Ph.D., Founder, President and Chief Executive Officer, will present a corporate update at 11:30 a.m. EST. Operator Calithera Biosciences CEO Susan Molineaux's 2020 pay jumps 64% to $3.6M. The BIO CEO and Investor meeting is being held at the Waldorf Astoria in New York City. Company profile page for Calithera Biosciences Inc including stock price, company news, press releases, executives, board members, and contact information CALITHERA BIOSCIENCES INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents. Calithera Biosciences (CALA) clinical-stage company announced they will be offering up 4,500,000 shares of common stock in an underwritten public offering. By ExecPay News. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. Phone Number (650) 870-1000. Calithera Biosciences CEO Susan Molineaux's 2019 pay rises 9% to $2.2M. Furthermore, CEO Susan … Its 52-week range is between 1.87 and 6.18, which gives CALA stock a 52-week price range ratio of 9.51% Jocel Dumlao “Calithera Biosciences provides a robust environment for drug discovery by combining highly integrated and experienced teams.” Eric B. Sjogren, Ph.D. “Working at Calithera is stimulating and rewarding on many levels, scientifically and personally.” Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Dr. Molineaux was most recently a founder, CSO and CEO of Proteolix, a company that discovered and developed proteasome inhibitors for the treatment of cancer and autoimmune disease. How Does Total Compensation For Susan Molineaux Compare With Other Companies In The Industry? Calithera Biosciences Inc (CALA) Q1 2021 Earnings Call Transcript Motley Fool Transcribers 14 mins ago Gold settles at a nearly 3-month high … And for technical investors there is … Calithera Biosciences CEO Susan Molineaux's 2015 pay jumps 266% to $3.4M Calithera Biosciences reports 2015 executive compensation. April 23, 2021. Search and apply for the latest Executive assistant to chief information officer jobs in South San Francisco, CA. Prior to starting Calithera, Dr. Molineaux was a co-founder of Proteolix and served as the CSO for two years before becoming President and CEO … Susan Molineaux, PhD, President and CEO of Calithera, commented: "We are pleased that CB-839 has been granted Fast Track designation, demonstrating the FDA’s commitment to facilitate the development and expedite the review of our glutaminase inhibitor as an important new therapy for patients with relapsed renal cell carcinoma. Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Competitors of Caliva include Planet 13 Holdings, dosist and Flower One.. Where is Caliva headquarters?. Susan Molineaux – Founder, President and Chief Executive Officer. Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q2 2019 Results - Earnings Call Transcript Aug. 08, 2019 10:08 PM ET Calithera Biosciences, Inc. (CALA) 10 … Glassdoor gives you an inside look at what it's like to work at Calithera Biosciences, including salaries, reviews, office photos, and more. RICHMOND, Calif., Feb. 27, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, today announced the appointment of Kathy Yi as senior vice president and chief financial officer, to succeed current executive vice president and chief financial officer H. Ward Wolff, who will be retiring from the company in early March. Dr. Molineaux is a co-founder of Calithera Biosciences and has served as the company’s Chief Executive Officer since the company’s founding in June 2010. This is the Calithera Biosciences company profile. Did You Miss Calithera Biosciences's 37% Share Price Gain? Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q1 2021 Results - Earnings Call Transcript. Calithera Biosciences Inc ... Susan M. Molineaux-- Founder, President and Chief Executive Officer. Calithera Biosciences. Prior to starting Calithera, Dr. Molineaux was a co-founder of Proteolix and served as the CSO for two years before becoming President and CEO of the company. Calithera Biosciences CEO Susan Molineaux's 2015 pay jumps 266% to $3.4M Calithera Biosciences reports 2015 executive compensation. According to our data, Calithera Biosciences, Inc. has a market capitalization of US$354m, and paid its CEO total annual compensation worth US$2.0m over the year to December 2018. San Francisco Bay Area. Published: April 29, 2016. Calithera Biosciences Inc. 343 Oyster Point Boulevard. Calithera Biosciences Inc ... Susan M. Molineaux-- Founder, President & Chief Executive Officer. Prior to joining Portola, Mr. Garland was President of Relypsa, which was acquired by Vifor Pharma in 2016. Company Participants. SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today announced the expansion of the company’s ongoing clinical trial evaluating telaglenastat in … Susan Molineaux has been the CEO of Calithera Biosciences, Inc. (NASDAQ:CALA) since 2010, and this article will examine the executive's compensation with respect to the overall performance of the company.This analysis will also look to assess whether the CEO is appropriately paid, considering recent earnings growth and investor returns for Calithera Biosciences. The one-year performance of Calithera Biosciences Inc. stock is -54.13 %, while year-to-date (YTD) performance is -53.56 %. Harneet Rishi. Current investors in Caliva, LCV, and Subversive LPs doubled down on their support and we are also honored to have artists like Rihanna, Meek â ¦ Darn! Jennifer McNealey - IR. Founders Susan M. Molineaux. Calithera is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity. Susan Molineaux has been the CEO of Calithera Biosciences, Inc. (NASDAQ:CALA) since 2010. Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. Senior Vice President, Drug Discovery at Calithera Biosciences San Francisco Bay Area 484 connections. Calithera Biosciences Inc. Calithera Biosciences, Inc. provides pharmaceutical products. SOUTH SAN FRANCISCO, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that preclinical data highlighting the potential of CB-708, the company’s … Calithera Biosciences is headquartered in South San Francisco. Business Description Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. Mr. Garland is Chief Executive Officer of PACT Pharma. DJ Calithera Biosciences, Inc. CEO Susan Molineaux on Q1 2021 Results -- Earnings Call Transcript >CALA Last Funding Type Grant. President, Chief Executive Officer & Director Susan M. Molineaux founded Calithera Biosciences, Inc. and Proteolix, Inc. 2 Calithera Biosciences reviews. Dr. Molineaux co-founded Proteolix, a biopharmaceutical company, where she served in various roles, including Chief Executive Officer, and Chief Scientific Officer until Proteolix’s acquisition by Onyx Pharmaceuticals. At this time, all participants are in a listen-only mode. Prior to joining PACT, Mr. Garland was President and CEO of Portola Pharmaceuticals prior to its acquisition by Alexion in July 2020. What's more, Calithera CEO Susan Molineaux, who led Proteolix Inc. into a 2009 deal that delivered the multiple myeloma drug Kyprolis to Onyx … --$102.9 Million in Cash and Investments at March 31, 2021-- -- Conference Call and Webcast Scheduled for 2:00 p.m. PT on May 6, 2021-- SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of … NEW YORK – San Francisco-based Calithera Biosciences on Thursday said that it had dosed the first patient in a Phase II clinical trial of its investigational agent telaglenastat plus chemotherapy and the immune checkpoint inhibitor pembrolizumab (Merck's Keytruda) in first-line advanced, KEAP1- or NRF2-mutated non-small cell lung cancer. Senior Vice President, Drug Discovery at Calithera Biosciences San Francisco Bay Area 484 connections. Read employee reviews and ratings on Glassdoor to decide if Calithera Biosciences … Dr. Molineaux has served as our President, Chief Executive Officer, and as a member of our board of directors since she co-founded Calithera in 2010. Calithera’s diverse Board of Directors provides the governance and expertise to guide our discovery and development efforts for our investigational onco-metabolic therapies. Dr. Agarwal is Chief Development Officer and Head Portfolio Strategy at Sana Biotechnology. John Albert Molineaux Marte Encargado de planificación de logística en Digiflex SRL. Calithera Biosciences. 10/01/2015 at 8:00 AM EDT: Calithera Biosciences, Inc. at Leerink Partners Inaugural Immuno-Oncology Roundtable. Join to Connect Calithera Biosciences. Dr. Molineaux is the co-founder, President and CEO of Calithera Biosciences, a start-up company that commenced operations in June of 2010. Calithera Biosciences's key executives are Curtis C. Hecht, Susan M. Molineaux and Keith Orford.. How many employees does Calithera Biosciences have?. Click here for webcast. About I have served as President, Chief Executive Officer and as a member of the board of directors at Calithera Biosciences since I co-founded the company in March 2010. Operating Status Active. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera … Glassdoor gives you an inside look at what it's like to work at Calithera Biosciences, including salaries, reviews, office photos, and more. According to Calithera President and CEO Susan Molineaux, among the company's various pipeline opportunities, there is a strong biological rationale to continue to study telaglenastat, a glutaminase inhibitor, in KEAP1/NRF2-mutated NSCLC patients in the KEAPSAKE trial. Contact Email info@Calithera.com. Calithera Biosciences. Full-time, temporary, and part-time jobs. Calithera Biosciences was founded in 2010.. Who are Calithera Biosciences key executives?. Calithera Biosciences, Inc. at 2016 BIO CEO & Investor Conference. Calithera Biosciences, Inc. (NASDAQ:CALA) Q3 2020 Earnings Conference Call November 5, 2020 5:00 PM ET. Calithera Biosciences, Inc. CALA has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. Okay, thank you. Former Portola Pharmaceuticals President and Chief Executive Officer Brings Extensive Executive Leadership and Commercial Oncology ExperienceSOUTH SAN FRANCISCO, Calif., … Calithera Biosciences, Inc. Common Stock, also called Calithera Biosciences, is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. Thank you for standing by. Frequently Asked Questions. CEO at Calithera Biosciences South San Francisco, CA. Job email alerts. Calithera Biosciences reported fiscal year 2015 executive compensation information on April 29, 2016. --CB-708 is an oral small molecule inhibitor of CD73 in preclinical development for oncology--Antengene is granted exclusive rights to develop and commercialize asset discovered and initially developed by Calithera SOUTH SAN FRANCISCO, Calif. and SHANGHAI, China, May 17, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology … SOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today shared final results from the Phase 2 CANTATA study evaluating the company’s glutaminase … Calithera to Present at the Jefferies 2021 Virtual Healthcare Conference May 17, 2021 Calithera Biosciences and Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708 May 6, 2021 Calithera Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights April 30, 2021 The 18 th Annual BIO CEO & Investor Conference On Tuesday, February 9, 2016, Christopher J. Molineaux, Ph.D., Senior Vice President of Development, will present a corporate update at 2:30 pm EST. Alexander Louie. South San Francisco, California 94080-9992. Dr. Molineaux is the co-founder, President and CEO of Calithera Biosciences, a start-up company that commenced operations in June of 2010. These candid discussions take place in a secure, confidential setting. Thanks all for joining today and have a good evening. Calithera Biosciences reported fiscal year 2015 executive compensation information on April 29, 2016. SOUTH SAN FRANCISCO, Calif., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, announced that clinical data from its lead product candidate CB-839, a first-in-class glutaminase inhibitor, will be presented in a plenary session at the 28th EORTC-NCI-AACR … CEO at Calithera Biosciences. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California. While this analysis focuses on total compensation, it's worth noting the … 1 year ago - Seeking Alpha. Legal Name Calithera Biosciences, Inc. Stock Symbol NASDAQ:CALA. Dr. Molineaux was most recently a founder, CSO and CEO of Proteolix, a company that discovered and developed proteasome inhibitors for the treatment of cancer and autoimmune disease. ### Contacts: Susan M. Molineaux, PhD President and CEO Calithera Biosciences info@calithera.com. Calithera Biosciences has 79 employees. John Albert Molineaux Marte. Prior to Relypsa, Mr. Garland was […] While this analysis focuses on total compensation, it's worth noting the salary is … Company Type For Profit. According to our data, Calithera Biosciences, Inc. has a market capitalization of US$354m, and paid its CEO total annual compensation worth US$2.0m over the year to December 2018. Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. Competitive salary. Calithera Biosciences Inc () Stock Market info Recommendations: Buy or sell Calithera Biosciences stock? Dr. Molineaux co-founded Proteolix, a biopharmaceutical company, where she served in various roles, including Chief Executive Officer, and Chief Scientific Officer until Proteolix’s acquisition by Onyx Pharmaceuticals.
calithera biosciences ceo
CALITHERA BIOSCIENCES INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. The funds will be used to expand the firmâ s range of marketing and advertising services. Industry Pharmaceuticals. Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. When the results of an employee survey came through in May 2020, Nucleus Global CEO Dan Bridges, who is based in London, clicked open the file … and breathed a huge sigh of relief: 98% of employees gave the leadership team high marks for its handling … Click here for webcast. Apr 2013 – Present6 years 8 months. Well, this is Susan. Thanks all for joining today and have a good evening. Insider Ownership Of Calithera Biosciences. Who Participates Biotech… Read More About Published: April 29, 2016. SOUTH SAN FRANCISCO, Calif., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that preliminary safety and efficacy data from an investigator-sponsored trial … SOUTH SAN FRANCISCO, Calif., Feb. 3, 2015 -- Calithera Biosciences, Inc. , a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against... | May 23, 2021 The Company is focused on discovering and developing novel … Corporate Profile. Phone 1 650 870-1000. All content is posted anonymously by employees working at Calithera Biosciences. CALA stock has a five-year performance of -52.5 %. On Tuesday, February 14, 2017, Susan Molineaux, Ph.D., Founder, President and Chief Executive Officer, will present a corporate update at 11:30 a.m. EST. Operator Calithera Biosciences CEO Susan Molineaux's 2020 pay jumps 64% to $3.6M. The BIO CEO and Investor meeting is being held at the Waldorf Astoria in New York City. Company profile page for Calithera Biosciences Inc including stock price, company news, press releases, executives, board members, and contact information CALITHERA BIOSCIENCES INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents. Calithera Biosciences (CALA) clinical-stage company announced they will be offering up 4,500,000 shares of common stock in an underwritten public offering. By ExecPay News. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. Phone Number (650) 870-1000. Calithera Biosciences CEO Susan Molineaux's 2019 pay rises 9% to $2.2M. Furthermore, CEO Susan … Its 52-week range is between 1.87 and 6.18, which gives CALA stock a 52-week price range ratio of 9.51% Jocel Dumlao “Calithera Biosciences provides a robust environment for drug discovery by combining highly integrated and experienced teams.” Eric B. Sjogren, Ph.D. “Working at Calithera is stimulating and rewarding on many levels, scientifically and personally.” Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Dr. Molineaux was most recently a founder, CSO and CEO of Proteolix, a company that discovered and developed proteasome inhibitors for the treatment of cancer and autoimmune disease. How Does Total Compensation For Susan Molineaux Compare With Other Companies In The Industry? Calithera Biosciences Inc (CALA) Q1 2021 Earnings Call Transcript Motley Fool Transcribers 14 mins ago Gold settles at a nearly 3-month high … And for technical investors there is … Calithera Biosciences CEO Susan Molineaux's 2015 pay jumps 266% to $3.4M Calithera Biosciences reports 2015 executive compensation. April 23, 2021. Search and apply for the latest Executive assistant to chief information officer jobs in South San Francisco, CA. Prior to starting Calithera, Dr. Molineaux was a co-founder of Proteolix and served as the CSO for two years before becoming President and CEO … Susan Molineaux, PhD, President and CEO of Calithera, commented: "We are pleased that CB-839 has been granted Fast Track designation, demonstrating the FDA’s commitment to facilitate the development and expedite the review of our glutaminase inhibitor as an important new therapy for patients with relapsed renal cell carcinoma. Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Competitors of Caliva include Planet 13 Holdings, dosist and Flower One.. Where is Caliva headquarters?. Susan Molineaux – Founder, President and Chief Executive Officer. Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q2 2019 Results - Earnings Call Transcript Aug. 08, 2019 10:08 PM ET Calithera Biosciences, Inc. (CALA) 10 … Glassdoor gives you an inside look at what it's like to work at Calithera Biosciences, including salaries, reviews, office photos, and more. RICHMOND, Calif., Feb. 27, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, today announced the appointment of Kathy Yi as senior vice president and chief financial officer, to succeed current executive vice president and chief financial officer H. Ward Wolff, who will be retiring from the company in early March. Dr. Molineaux is a co-founder of Calithera Biosciences and has served as the company’s Chief Executive Officer since the company’s founding in June 2010. This is the Calithera Biosciences company profile. Did You Miss Calithera Biosciences's 37% Share Price Gain? Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q1 2021 Results - Earnings Call Transcript. Calithera Biosciences Inc ... Susan M. Molineaux-- Founder, President and Chief Executive Officer. Calithera Biosciences. Prior to starting Calithera, Dr. Molineaux was a co-founder of Proteolix and served as the CSO for two years before becoming President and CEO of the company. Calithera Biosciences CEO Susan Molineaux's 2015 pay jumps 266% to $3.4M Calithera Biosciences reports 2015 executive compensation. According to our data, Calithera Biosciences, Inc. has a market capitalization of US$354m, and paid its CEO total annual compensation worth US$2.0m over the year to December 2018. San Francisco Bay Area. Published: April 29, 2016. Calithera Biosciences Inc. 343 Oyster Point Boulevard. Calithera Biosciences Inc ... Susan M. Molineaux-- Founder, President & Chief Executive Officer. Prior to joining Portola, Mr. Garland was President of Relypsa, which was acquired by Vifor Pharma in 2016. Company Participants. SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today announced the expansion of the company’s ongoing clinical trial evaluating telaglenastat in … Susan Molineaux has been the CEO of Calithera Biosciences, Inc. (NASDAQ:CALA) since 2010, and this article will examine the executive's compensation with respect to the overall performance of the company.This analysis will also look to assess whether the CEO is appropriately paid, considering recent earnings growth and investor returns for Calithera Biosciences. The one-year performance of Calithera Biosciences Inc. stock is -54.13 %, while year-to-date (YTD) performance is -53.56 %. Harneet Rishi. Current investors in Caliva, LCV, and Subversive LPs doubled down on their support and we are also honored to have artists like Rihanna, Meek â ¦ Darn! Jennifer McNealey - IR. Founders Susan M. Molineaux. Calithera is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity. Susan Molineaux has been the CEO of Calithera Biosciences, Inc. (NASDAQ:CALA) since 2010. Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. Senior Vice President, Drug Discovery at Calithera Biosciences San Francisco Bay Area 484 connections. Calithera Biosciences Inc. Calithera Biosciences, Inc. provides pharmaceutical products. SOUTH SAN FRANCISCO, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that preclinical data highlighting the potential of CB-708, the company’s … Calithera Biosciences is headquartered in South San Francisco. Business Description Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. Mr. Garland is Chief Executive Officer of PACT Pharma. DJ Calithera Biosciences, Inc. CEO Susan Molineaux on Q1 2021 Results -- Earnings Call Transcript >CALA Last Funding Type Grant. President, Chief Executive Officer & Director Susan M. Molineaux founded Calithera Biosciences, Inc. and Proteolix, Inc. 2 Calithera Biosciences reviews. Dr. Molineaux co-founded Proteolix, a biopharmaceutical company, where she served in various roles, including Chief Executive Officer, and Chief Scientific Officer until Proteolix’s acquisition by Onyx Pharmaceuticals. At this time, all participants are in a listen-only mode. Prior to joining PACT, Mr. Garland was President and CEO of Portola Pharmaceuticals prior to its acquisition by Alexion in July 2020. What's more, Calithera CEO Susan Molineaux, who led Proteolix Inc. into a 2009 deal that delivered the multiple myeloma drug Kyprolis to Onyx … --$102.9 Million in Cash and Investments at March 31, 2021-- -- Conference Call and Webcast Scheduled for 2:00 p.m. PT on May 6, 2021-- SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of … NEW YORK – San Francisco-based Calithera Biosciences on Thursday said that it had dosed the first patient in a Phase II clinical trial of its investigational agent telaglenastat plus chemotherapy and the immune checkpoint inhibitor pembrolizumab (Merck's Keytruda) in first-line advanced, KEAP1- or NRF2-mutated non-small cell lung cancer. Senior Vice President, Drug Discovery at Calithera Biosciences San Francisco Bay Area 484 connections. Read employee reviews and ratings on Glassdoor to decide if Calithera Biosciences … Dr. Molineaux has served as our President, Chief Executive Officer, and as a member of our board of directors since she co-founded Calithera in 2010. Calithera’s diverse Board of Directors provides the governance and expertise to guide our discovery and development efforts for our investigational onco-metabolic therapies. Dr. Agarwal is Chief Development Officer and Head Portfolio Strategy at Sana Biotechnology. John Albert Molineaux Marte Encargado de planificación de logística en Digiflex SRL. Calithera Biosciences. 10/01/2015 at 8:00 AM EDT: Calithera Biosciences, Inc. at Leerink Partners Inaugural Immuno-Oncology Roundtable. Join to Connect Calithera Biosciences. Dr. Molineaux is the co-founder, President and CEO of Calithera Biosciences, a start-up company that commenced operations in June of 2010. Calithera Biosciences's key executives are Curtis C. Hecht, Susan M. Molineaux and Keith Orford.. How many employees does Calithera Biosciences have?. Click here for webcast. About I have served as President, Chief Executive Officer and as a member of the board of directors at Calithera Biosciences since I co-founded the company in March 2010. Operating Status Active. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera … Glassdoor gives you an inside look at what it's like to work at Calithera Biosciences, including salaries, reviews, office photos, and more. According to Calithera President and CEO Susan Molineaux, among the company's various pipeline opportunities, there is a strong biological rationale to continue to study telaglenastat, a glutaminase inhibitor, in KEAP1/NRF2-mutated NSCLC patients in the KEAPSAKE trial. Contact Email info@Calithera.com. Calithera Biosciences. Full-time, temporary, and part-time jobs. Calithera Biosciences was founded in 2010.. Who are Calithera Biosciences key executives?. Calithera Biosciences, Inc. at 2016 BIO CEO & Investor Conference. Calithera Biosciences, Inc. (NASDAQ:CALA) Q3 2020 Earnings Conference Call November 5, 2020 5:00 PM ET. Calithera Biosciences, Inc. CALA has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. Okay, thank you. Former Portola Pharmaceuticals President and Chief Executive Officer Brings Extensive Executive Leadership and Commercial Oncology ExperienceSOUTH SAN FRANCISCO, Calif., … Calithera Biosciences, Inc. Common Stock, also called Calithera Biosciences, is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. Thank you for standing by. Frequently Asked Questions. CEO at Calithera Biosciences South San Francisco, CA. Job email alerts. Calithera Biosciences reported fiscal year 2015 executive compensation information on April 29, 2016. --CB-708 is an oral small molecule inhibitor of CD73 in preclinical development for oncology--Antengene is granted exclusive rights to develop and commercialize asset discovered and initially developed by Calithera SOUTH SAN FRANCISCO, Calif. and SHANGHAI, China, May 17, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology … SOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today shared final results from the Phase 2 CANTATA study evaluating the company’s glutaminase … Calithera to Present at the Jefferies 2021 Virtual Healthcare Conference May 17, 2021 Calithera Biosciences and Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708 May 6, 2021 Calithera Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights April 30, 2021 The 18 th Annual BIO CEO & Investor Conference On Tuesday, February 9, 2016, Christopher J. Molineaux, Ph.D., Senior Vice President of Development, will present a corporate update at 2:30 pm EST. Alexander Louie. South San Francisco, California 94080-9992. Dr. Molineaux is the co-founder, President and CEO of Calithera Biosciences, a start-up company that commenced operations in June of 2010. These candid discussions take place in a secure, confidential setting. Thanks all for joining today and have a good evening. Calithera Biosciences reported fiscal year 2015 executive compensation information on April 29, 2016. SOUTH SAN FRANCISCO, Calif., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, announced that clinical data from its lead product candidate CB-839, a first-in-class glutaminase inhibitor, will be presented in a plenary session at the 28th EORTC-NCI-AACR … CEO at Calithera Biosciences. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California. While this analysis focuses on total compensation, it's worth noting the … 1 year ago - Seeking Alpha. Legal Name Calithera Biosciences, Inc. Stock Symbol NASDAQ:CALA. Dr. Molineaux was most recently a founder, CSO and CEO of Proteolix, a company that discovered and developed proteasome inhibitors for the treatment of cancer and autoimmune disease. ### Contacts: Susan M. Molineaux, PhD President and CEO Calithera Biosciences info@calithera.com. Calithera Biosciences has 79 employees. John Albert Molineaux Marte. Prior to Relypsa, Mr. Garland was […] While this analysis focuses on total compensation, it's worth noting the salary is … Company Type For Profit. According to our data, Calithera Biosciences, Inc. has a market capitalization of US$354m, and paid its CEO total annual compensation worth US$2.0m over the year to December 2018. Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. Competitive salary. Calithera Biosciences Inc () Stock Market info Recommendations: Buy or sell Calithera Biosciences stock? Dr. Molineaux co-founded Proteolix, a biopharmaceutical company, where she served in various roles, including Chief Executive Officer, and Chief Scientific Officer until Proteolix’s acquisition by Onyx Pharmaceuticals.
Florida Honeymoon Packages, Georgia Alice Bobby Pant, Upcoming Football Trials In Bangalore 2020how Was The Rabies Vaccine Developed, How To Find Common Difference In Harmonic Progression, Vegalta Vs Shimizu Sofascore, How To Calculate Shear Force, Rival Adversary Crossword Clue,